News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
1 hr ago | Bloomberg
Bristol-Myers Squibb Co. , the maker of the anti-psychotic drug Abilify, reported second-quarter profit that topped analysts' estimates on sales of its cancer medicine Yervoy and blood thinner Eliquis.
Our regular readers know that we have been using the idea of buying on the dips and searching for value while investing in this bull market the past few years.
Lawyers who battled Pfizer Inc. for more than a decade over women's cancers linked to the company's Prempro menopause drug settled a rare public dispute over $62 million in fees.
ATRA, a clinical-stage biopharmaceutical firm, engaged in the development of treatments for muscle wasting conditions, plans to raise $75.0 million in its upcoming IPO.
The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Wednesday, with over 377,000 shares traded versus three month average volume of about 101,000.
Although we did not see a positive neratinib ExteNET outcome in adjuvant breast cancer as a complete surprise, we believe the magnitude of benefit is among best-case scenarios that could be envisioned.
July 23, 2014 By Renee Morad , BioSpace.com Breaking News Staff Puma Biotechnology Inc. announced an amendment to its licensing agreement with Pfizer regarding its investigational cancer drug neratinib, or PB272.
Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.
A top Democrat warned on Tuesday a recent string of so-called tax inversions could foreshadow future moves as U.S. firms look to dodge American taxes.
Watching big pharmaceutical companies and other major U.S. corporations line up to make foreign acquisitions that will bring them a low-tax haven as headquarters, a middle market CEO/owner/entrepreneur could easily become jealous.
The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Pfizer is the #16 analyst pick.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Inc .
Note: We do not store your email address but your IP address will be logged to prevent abuse of this feature.
The Borough of West Chester early this week won the latest episode in a years-long court battle with drugmaker Pfizer over sewer payments owed to the borough by Wyeth, the pharmaceutical company that Pfizer bought in 2009 for $68 billion.
Updated: Thu Jul 24, 2014 07:18 am
Copyright © 2014 Topix LLC